Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
Summary
This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.
Detailed description
PRIMARY OBJECTIVE: I. Characterize differences in subjective CRCI longitudinally among patients receiving TKIs for CML or CLL. OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups. GROUP I: TKI recipients complete surveys, undergo cognitive assessments, undergo saliva sample collection, and have their medical records reviewed on study. GROUP II: Cancer-free individuals complete surveys, undergo cognitive assessments, undergo saliva sample collection, and have their medical records reviewed on study.
Arms & interventions
Outcome measures
Primary
Subjective cognitive performance
Will be assessed using the FACT-Cog. Will apply multilevel models to study data. Will include main effects of time, group, and the group X time interaction.
Time frame: 12 months
Eligibility criteria
Study locations (1)
University of Rochester NCORP Research Base
Rochester, New York, 14642